GlassScriptPhysician profile
John Steele Trickett
NPI 1861997090
$2,257.06
in general payments reported to CMS, 2019-2025
16 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $126 · 2024: $557 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.51 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $514.88 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $362.74 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $292.78 | 2022-2025 | Tezspire, Fasenra |
| Csl Behring | $198.31 | 2024-2025 | Haegarda, Andembry, Hizentra |
| Grifols USA, LLC | $176.85 | 2024 | Xembify |
| Novartis Pharmaceuticals Corporation | $141.71 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $139.65 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $106.05 | 2024-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Optinose US, INC. | $55.81 | 2025 | |
| Genentech USA, INC. | $52.14 | 2025 | Xolair |
| Alk-Abello, INC | $50.00 | 2023 | Grastek, Odactra, Ragwitek |
| Abbvie INC. | $34.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2025 | Cuvitru |
| Amgen INC. | $17.51 | 2025 | Tezspire |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $17.26 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Trickett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.